Advertisement

Reviews in Endocrine and Metabolic Disorders

, Volume 3, Issue 3, pp 211–224 | Cite as

Pharmacokinetics and Potency of Progestins used for Hormone Replacement Therapy and Contraception

  • Frank Z. Stanczyk
Article
progestrins classification structure-function relationships pharmacokinetics potency 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Stanczyk FZ, Henzl MR. Use of the name “progestin”. Contraception 2001;64:1-2.Google Scholar
  2. 2.
    Henzl MR. Contraceptive hormones and their clinical use. In: Yen SSC, Jaffe RE, eds. Reproductive Endocrinology, physiology, Pathophysiology, and Clinical Management. Philadelphia: WB Saunders, 1986;643-682.Google Scholar
  3. 3.
    Stanczyk FZ. Pharmacokinetics of progestogens. Int Proc J 1989;1:11-20.Google Scholar
  4. 4.
    Stanczyk FZ. Introduction: Structure-function relationships, metabolism, pharmacokinetic and potency of progestins. Drugs Today 1996;32(Suppl H):1-14.Google Scholar
  5. 5.
    Stanczyk FZ. Structure-function relationships, potency and pharmacokinetics of progestogens. In: Lobo RA, ed. Treatment the Postmenopausal Woman: Basic and Clinical Aspects. Second Edition. Philadelphia: Lippincott, Williams and Wilkins, 1999;105-124.Google Scholar
  6. 6.
    Stanczyk FZ, Roy S. Metabolism of levonorgestrel, norethindrone, and structurally related contraceptive steroids. Contraception 1990;42:67-96.Google Scholar
  7. 7.
    Edgren RA, Stanczyk FZ. Nomenclature of the gonane progestins. Contraception 1999;60:313.Google Scholar
  8. 8.
    Stancyzk FZ. Pharmacokinetics of progesterone administered orally and parenterally. In: Sitruk-Ware R, Mishell DR, Jr. eds. Progestins and Antiprogestins in Clinical Practice. New York: Marcel-Dekker, 2000;393-400.Google Scholar
  9. 9.
    Simon JA, Robinson DE, Andrews MC, Hildebrand JR III, Rocci ML, Jr., Blake RE, Hodgen GD. The absorption of oral micronized progesterone: the effect of food, dose proportionality, and comparison with intramuscular progesterone. Fertil and Steril 1993;60:26-33.Google Scholar
  10. 10.
    Padwick ML, Endacott J, Matson C, Whitehead MI. Absorption and metabolism of oral progesterone when administered twice daily. Fertil Steril 1986;46:402-407.Google Scholar
  11. 11.
    Sitruk-Ware R, Progestins in hormonal replacement therapy and prevention of endometrial disease. In: Sitruk-Ware R, Mishell DR, Jr, eds. Progestins and Anti-Progestins in Clinical Practice. New York: Marcel Dekker, 2000;269-287.Google Scholar
  12. 12.
    Hiroi M, Stanczyk FZ, Goebelsmann U, Brenner PF, Lumkin ME, Mishell DR, Jr. Radioimmunoassay of serum medroxyprogesterone acetate (Provera) in women following oral and intravaginal administration. Steroids 1975;26:373-386.Google Scholar
  13. 13.
    Svensson L-O, Johnson SH, Olsson S-E. Plasma concentrations of medroxyprogesterone acetate, estradiol and estrone following oral administration of Klimaxil®, Trisequence®/Provera® and Divina®. A randomized, single-blind, triple cross-over bioavailability study in menopausal women. Maturitas 1994;18:229-238.Google Scholar
  14. 14.
    Mathrubutham M, Fotherby K. Medroxyprogesterone acetate in human serum. J Serum Biochem 1981;14:783-786.Google Scholar
  15. 15.
    Victor A, Johansson ED. Pharmacokinetic observations on medroxyprogesterone acetate asdministered orally and intravaginally. Contraception 1976;14:319-329.Google Scholar
  16. 16.
    Farinha A, Bica A, Tavares P. Improved bioavailability of micronized megestrol acetate tablet formulation in humans. Drug Devel Indust Pharm 2000;26:567-2000.Google Scholar
  17. 17.
    Kuhnz W, Staks T, Jütting G. Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles. Contraception 1993a;48:557-575.Google Scholar
  18. 18.
    Kuhl H. Pharmacokinetics of oestrogens and progestogens. Maturitas 1990;12:171-197.Google Scholar
  19. 19.
    Dugwekar YC, Narula RK, Laumas KR. Disappearance of 1?-3H chlormadinone acetate from the plasma of women. Contraception 1973;7:27-45.Google Scholar
  20. 20.
    Lin W-J, Her S-J, Chen P-F, Chen RR-L. Determination of medrogestone in plasma by high-performance liquid chromatography. J Chromatography 1998;714:263-268.Google Scholar
  21. 21.
    Ezan E, Benech H, Bucourt R, Ardouin T, Tchernatinsky C, Thomas J-L, Paris J, Grognet J-M. Enzyme immunoassay for nomegestrol acetate in human plasma. J Steroid Biochem 1993;46:507-514.Google Scholar
  22. 22.
    Back DJ, Brackenridge AM, Crawford FE, McIver M, Orme ML'E, Rowe PH, Smith E. Kinetics of norethindrone in women. II. Single-dose kinetics. Clin Pharmacol Ther 1978;24:448-453.Google Scholar
  23. 23.
    Stanczyk FZ, Mroszczak EJ, Ling T, Runkel R, Henzl M, Miyakawa I, Goebelsmann U. Plasma levels and pharmacokinetics of norethindrone and ethinylestradiol administered in solution and as tablets to women. Contraception 1983;28:241-251.Google Scholar
  24. 24.
    Odlind V, Weiner E, Victor A, Johansson EDB. Plasma levels of norethindrone after single oral dose administration of norethindrone and lynestrenol. Clin Endocrinol 1979;10:29-38.Google Scholar
  25. 25.
    Kuhnz W, Huener A, Humpel M, Seifert W, Michaelis K. In vivo conversion of norethesterone and norethisterone acetate to ethinyl estradiol in postmenopausal women. Contraception 1997;56:379-385.Google Scholar
  26. 26.
    Humpel M, Wendr H, Dogs G, Weib CHR, Rietz S, Speck U. Intraindividual comparison of pharmacokinetics parameters of d-norgestrel, lynestrenol and cyproterone acetate in 6 women. Contraception 1977;16:199-215.Google Scholar
  27. 27.
    Goebelsmann U, Hoffman D, Chiang S. Woutersz T. The relative bioavailability of levonorgestrel and ethinyl estradiol administered as a low-dose combination oral contraceptive. Contraception 1986;34:341-351.Google Scholar
  28. 28.
    Stanczyk FZ, Lobe RA, Chiange ST, Woutersz TB. Pharmacokinetic comparison of two triphasic oral contraceptive formulations containing levonorgestrel and ethinylestradiol. Contraception 1990;41:39-53.Google Scholar
  29. 29.
    Back DJ, Bates M, Breckenridge AM, Hall JM, MacIver M. Levonorgestrel and ethinylestradiol in women-studies wit Ovran and Ovranette. Contraception 1981;23:229-239.Google Scholar
  30. 30.
    Humpel M, Wendt H, Pommerenke G, Weib CHR, Speck U. Investigations of pharmacokinetics of levonorgestrel to specific consideration of a possible first pass effect in women. Contraception 1978;17:207-220.Google Scholar
  31. 31.
    McGuire JL, Phillips A, Hahn DW, Tolman EL, Flor S, Kafrissen ME. Pharmacologic and pharmacokinetic characteristics of norgestimate. Am J Obstet Gynecol 1990;163:2127-2131.Google Scholar
  32. 32.
    Kuhnz W, Blode H, Mahler M. Systemic availability of levonorgestrel after single oral administration of a norgestimate-containing oral contraceptive to 12 women. Contraception 1993b;47:283-294.Google Scholar
  33. 33.
    Hasenack HG, Bosch AMG, Kaar K. Serum levels of 3-ketodesogestre after oral administration pf desogestrel and 3-ketodesogestrel. Contraception 1986;33:591-596.Google Scholar
  34. 34.
    Bergink W, Assendrop R, Koosterboer L, van Lier W, Voortman G, Qvist I. Serum pharmacokinetics of orally administered desogestrel and binding of contraceptive progestogens to sex hormone-binding globulin. Am J Obstet Gynecol 1990;163:2132-2137.Google Scholar
  35. 35.
    Back DJ, Grimmer SFM, Shenoy N, Orme MLE. Plasma concentrations of 3-ketodesogestrel after oral administration of desogestrel and intravenous administration of 3-ketodesogestrel. Contraception 1987;35:619-626.Google Scholar
  36. 36.
    Orme M, Back DJ, Ward S, Green S. The pharmacokinetics of ethinyl estradiol in the presence and absence of gestodene and desogestrel. Contraception 1991;43:305-316.Google Scholar
  37. 37.
    Kuhl H, Jung-Hoffman C, Heidt F. Serum levels of 3-ketodesogestrel and SHBG during 12 cycles of treatment with 30 ?g desogestrel. Contraception 1988a;38:381-390.Google Scholar
  38. 38.
    Tauber U, Tack JW, Matthes H. Single dose pharmacokinetics of gestodene in women after intravenous and oral administration. Contraception 1989;40:461-479.Google Scholar
  39. 39.
    Kuhl H, Jung-Hoffman C, Heidt F. Alterations in the serul levels of gestodene and SHBG during 12 cycles of treatment with 30 mg ethinyl estradiol and 75 mg gestodene. Contraception 1988b;38:477-486.Google Scholar
  40. 40.
    Fotherby K. Potency and pharmacokinetics of gestagens. Contraception 1990;41:533-550.Google Scholar
  41. 41.
    Oettel M, Bervoas-Martín, Elger W, Golbs S, Hobe G, Kaufmann G, Mathieu, Moore C, Puri C, Ritter P, Reddersen G, Schön, Strauch G, Zimmerman H. A 19-norprogestin without a 17?-ethinyl group. I: Dienogest from a pharmacokinetic point of view. Drugs Today 1995;31:499-516.Google Scholar
  42. 42.
    Blode H, Wuttke W, Loock W, Röll G, Heithecker R. A 1-year pharmacokinetic investigation of a novel oral contraceptive containing drospirenone in healthy female volunteers. Eur J Contraception Reprod Health Care 2000;5:256-264.Google Scholar
  43. 43.
    Krattenmacher R. Drospirenone: Pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000;62:29-38.Google Scholar
  44. 44.
    Edgren RA, Sturtevant FM. Potencies of oral contraceptives. Am J Obstet Gynecol 1976;125:1029-1038.Google Scholar
  45. 45.
    Edgren RA. Progestational potency of oral contraceptives: A polemic. Int J Fertil 1978;23:162-169.Google Scholar
  46. 46.
    Edgren RA. Relative potencies of oral contraceptives. In: Moghissi KS, ed. Controversies to Contraception. Baltimore: Williams & Wilkins, 1979:1-19.Google Scholar
  47. 47.
    Edgren RA. Progestins. In: Givens JR, ed. Clinical use of sex Steroids. Chicago: Year Book Medical Publishers, 1980;1-29.Google Scholar
  48. 48.
    Juchem M, Pollow K. Binding of oral contraceptive progestins to serum proteins and cytoplasmic receptor. Am J Obstet Gynecol 1990;2171-2182.Google Scholar
  49. 49.
    Phillips A, Demarest DW, Hahn F, Wong F, McGuire JL. Progestational and androgenic receptor binding affinities and in vivo activities of norgestimate and other progestins. Contraception 1990;41:399-410.Google Scholar
  50. 50.
    Swyer GIM, Little V. Clinical assessment of relative potency of progestagens. J Reprod Fert, 1968;(Suppl. 5):63-68.Google Scholar
  51. 51.
    Swyer GIM. Potency of progestins in oral contraceptives-further delay of menses data. Contraception 1982;26:23-27.Google Scholar
  52. 52.
    Briggs MH. Progestins: Toxicological studies in animal models. In: Benagiano G, Zulli P, Diszfalusy E, eds. Progestins in Therapy. New York: Raven Press, 1983.Google Scholar
  53. 53.
    Dorflinger LJ. Relative potency of progestins used in oral contraceptives. Contraception 1985;31:557-570.Google Scholar
  54. 54.
    Whitehead MI, Townsend PT, Pryse-Davies J, Ryder TA, King RJB. Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. N Engl J Med 1981;305:1599.Google Scholar
  55. 55.
    Whitehead MI, Townsend PT, Pryse-Davies J, Ryder T, Lane G, Siddle NC, King RJB. Effects of various types and dosages of progestins on the postmenopausal endometrium. J Reprod Med 1982;27:539.Google Scholar
  56. 56.
    Lane G, Siddle NC, Ryder TA, Pryse-Davies J, King RJB, Whitehead MI. Dose dependent effects of oral progesterone on the oestrogenised postmenopausal endometrium. Br Med J 1983;287:1241.Google Scholar
  57. 57.
    Whitehead M, Lane G, Siddle N, Townsend P, King R. Avoidance of endometrial hyperstimulatin in estrogen-treated postmenopausal women. Semin Reprod Endocrinol 1983;1:41.Google Scholar
  58. 58.
    Whitehead MI, Siddle NC, Townsend PT, Lane G, King RJB. The use of progestins and progesterone in the treatment of climacteric and postmenopausal symptoms. In: Bardin CW, Milgrom E, Mauvais Jarvis P, eds. Progesterone and Progestins. New York: Raven Press, 1983;277.Google Scholar
  59. 59.
    Lane G, Siddle NC, Ryder TA, Pryse-Davies J, King RJB, Whitehead MI. Effects of dydrogesterone on the oestrogenized postmenopausal endometrium. Br J Obstet Gynaecol 1986a;93:55.Google Scholar
  60. 60.
    Lane G, Siddle NC, Ryder TA, Pryse-Davies J, King RJB, Whitehead MI. Is Provera the ideal progestin for addition to postmenopausal estrogen therapy? Fertil Steril 1986b;45:345.Google Scholar
  61. 61.
    King RJB, Whitehead MI. Assessment of the potency of orally administered progestins in women. Fertil Steril 1986;46:1062-1066.Google Scholar
  62. 62.
    Teichman AT. Levonorgestrel. Stuart-George Thieme Verlag, 1990;43.Google Scholar
  63. 63.
    Thorneycroft IH, Stanczyk FZ, Bradshaw KD, Ballagh SA, Nichols M, Weber ME. Effect of low-dose contraceptives on androgenic markers and acne. Contraception 1999;60:255-262.Google Scholar

Copyright information

© Kluwer Academic Publishers 2002

Authors and Affiliations

  • Frank Z. Stanczyk
    • 1
  1. 1.Departments of Obstetrics and Gynecology, and Preventive MedicineUniversity of Southern California, Keck School of MedicineLos AngelesUSA

Personalised recommendations